Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...

Enfortumab vedotin plus pembrolizumab is more effective than chemotherapy as first-line treatment for metastatic urothelial cancer, data suggest.

CureVac (CVAC) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase 1 clinical ...

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, ...

NIH researchers discovered that a new form of personalized cancer immunotherapy dramatically improved the treatment’s ...

Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that treatment.

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...